Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update

Vigil Neuroscience, Inc. (NASDAQ:VIGL) was the target of a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 685,800 shares, a decline of 23.7% from the August 15th total of 899,200 shares. Based on an average daily volume of 503,100 shares, the short-interest ratio is currently 1.4 days. Approximately 3.6% of the company’s stock are short sold.

Institutional Investors Weigh In On Vigil Neuroscience

Several large investors have recently modified their holdings of the stock. Point72 Asset Management L.P. bought a new position in Vigil Neuroscience during the second quarter valued at $5,940,000. Vanguard Group Inc. increased its holdings in Vigil Neuroscience by 11.9% during the 1st quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock worth $3,050,000 after acquiring an additional 95,276 shares during the period. Ensign Peak Advisors Inc lifted its stake in Vigil Neuroscience by 72.8% in the 2nd quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after purchasing an additional 166,442 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Vigil Neuroscience by 19.2% in the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock valued at $286,000 after purchasing an additional 11,536 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Vigil Neuroscience during the 2nd quarter valued at $87,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Trading Down 0.3 %

VIGL stock opened at $3.67 on Friday. Vigil Neuroscience has a 1-year low of $2.47 and a 1-year high of $9.24. The stock has a market cap of $145.52 million, a P/E ratio of -1.73 and a beta of 1.96. The stock’s fifty day simple moving average is $3.75 and its two-hundred day simple moving average is $3.52.

Vigil Neuroscience (NASDAQ:VIGL) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.02. As a group, analysts forecast that Vigil Neuroscience will post -2.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on the company. HC Wainwright restated a “buy” rating and issued a $17.00 target price on shares of Vigil Neuroscience in a report on Wednesday, August 14th. Guggenheim cut their price objective on shares of Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th. Finally, Wedbush reiterated an “outperform” rating and issued a $23.00 target price on shares of Vigil Neuroscience in a report on Thursday, July 11th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Vigil Neuroscience has a consensus rating of “Moderate Buy” and an average price target of $16.60.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.